Put Meds for Alzheimer Disease in Perspective

July 2025

About 7 million people age 65 years and older in the US have Alzheimer dementia...and it’s expected to double by 2050.

Be ready to put meds for Alzheimer disease (AD) in perspective.

Anti-amyloid monoclonal antibodies donanemab (Kisunla) and lecanemab (Leqembi) target and reduce amyloid beta plaques in the brain.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote